Resveratrol Preconditioning Protects Against Cerebral Ischemic Injury via Nuclear Erythroid 2-Related Factor 2

Stroke

Volumn 46, Issue 6, 2015, Pages 1626-1632

  Narayanan, Srinivasan V ^a   Dave, Kunjan R ^a   Saul, Isa ^a   Perez Pinzon, Miguel A ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

ischemic preconditioning; mitochondria; reactive oxygen species; resveratrol

Indexed keywords

DNA; MANGANESE SUPEROXIDE DISMUTASE; NAD(P)H QUINONE OXIDOREDUCTASE 1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2; ANTIOXIDANT; NEUROPROTECTIVE AGENT; NFE2L2 PROTEIN, MOUSE; NFE2L2 PROTEIN, RAT; NONSTEROID ANTIINFLAMMATORY AGENT; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ASTROCYTE CULTURE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN LEVEL; BRAIN MITOCHONDRION; CELL FUNCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MALE; MITOCHONDRIAL RESPIRATION; MOUSE; NEUROPHARMACOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; UPREGULATION; WESTERN BLOTTING; ANIMAL; ASTROCYTE; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; METABOLISM; MITOCHONDRION; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; ASTROCYTES; BRAIN ISCHEMIA; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; MALE; MICE; MICE, KNOCKOUT; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; STILBENES;

EID: 84942897142     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.008921     Document Type: Article

References (28)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-322. doi: 10.1161/CIR.0000000000000152.
2. Della-Morte D, Dave KR, DeFazio RA, Bao YC, Raval AP, Perez-Pinzon MA. Resveratrol pretreatment protects rat brain from cerebral ischemic damage via a sirtuin 1-uncoupling protein 2 pathway. Neuroscience. 2009;159:993-1002. doi: 10.1016/j.neuroscience.2009.01.017.
3. Dave KR, Lange-Asschenfeldt C, Raval AP, Prado R, Busto R, Saul I, et al. Ischemic preconditioning ameliorates excitotoxicity by shifting glutamate/gamma-aminobutyric acid release and biosynthesis. J Neurosci Res. 2005;82:665-673. doi: 10.1002/jnr.20674.
4. Raval AP, Dave KR, Pérez-Pinzón MA. Resveratrol mimics ischemic preconditioning in the brain. J Cereb Blood Flow Metab. 2006;26:1141-1147. doi: 10.1038/sj.jcbfm.9600262.
5. Yan H, Jihong Y, Feng Z, Xiaomei X, Xiaohan Z, Guangzhi W, et al. Sirtuin 1-mediated inhibition of p66shc expression alleviates liver ischemia/reperfusion injury. Crit Care Med. 2014;42:e373-e381. doi:10.1097/CCM.0000000000000246.
6. Cavdar Z, Egrilmez MY, Altun ZS, Arslan N, Yener N, Sayin O, et al. Resveratrol reduces matrix metalloproteinase-2 activity induced by oxygen-glucose deprivation and reoxygenation in human cerebral microvascular endothelial cells. Int J Vitam Nutr Res. 2012;82:267-274. doi:10.1024/0300-9831/a000119.
7. Pérez-Alvarez A, Araque A. Astrocyte-neuron interaction at tripartite synapses. Curr Drug Targets. 2013;14:1220-1224.
8. Gürer G, Gursoy-Ozdemir Y, Erdemli E, Can A, Dalkara T. Astrocytes are more resistant to focal cerebral ischemia than neurons and die by a delayed necrosis. Brain Pathol. 2009;19:630-641. doi:10.1111/j.1750-3639.2008.00226.x.
9. Pehar M, Beeson G, Beeson CC, Johnson JA, Vargas MR. Mitochondriatargeted catalase reverts the neurotoxicity of hSOD1G9A astrocytes without extending the survival of ALS-linked mutant hSOD1 mice. PLoS One. 2014;9:e103438. doi: 10.1371/journal.pone.0103438.
10. Alvarez MI, Rivas L, Lacruz C, Toledano A. Astroglial cell subtypes in the cerebella of normal adults, elderly adults, and patients with Alzheimer's disease: a histological and immunohistochemical comparison. Glia. 2015;63:287-312. doi: 10.1002/glia.22751.
11. Miao SH, Sun HB, Ye Y, Yang JJ, Shi YW, Lu M, et al. Astrocytic JWA expression is essential to dopaminergic neuron survival in the pathogenesis of Parkinson's disease. CNS Neurosci Ther. 2014;20:754-762. doi:10.1111/cns.12249.
12. Ouyang YB, Voloboueva LA, Xu LJ, Giffard RG. Selective dysfunction of hippocampal CA1 astrocytes contributes to delayed neuronal damage after transient forebrain ischemia. J Neurosci. 2007;27:4253-4260. doi:10.1523/JNEUROSCI.0211-07.2007.
13. Nedergaard M, Ransom B, Goldman SA. New roles for astrocytes: redefining the functional architecture of the brain. Trends Neurosci. 2003;26:523-530. doi: 10.1016/j.tins.2003.08.008.
14. Bell KF, Fowler JH, Al-Mubarak B, Horsburgh K, Hardingham GE. Activation of Nrf2-regulated glutathione pathway genes by ischemic preconditioning. Oxid Med Cell Longev. 2011;2011:689524. doi:10.1155/2011/689524.
15. Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc. 2006;1:2406-2415. doi: 10.1038/nprot.2006.356.
16. Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN. Evaluating strategies to normalise biological replicates of Western blot data. PLoS One. 2014;9:e87293. doi: 10.1371/journal.pone.0087293.
17. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84-91.
18. Dave KR, DeFazio RA, Raval AP, Torraco A, Saul I, Barrientos A, et al. Ischemic preconditioning targets the respiration of synaptic mitochondria via protein kinase C epsilon. J Neurosci. 2008;28:4172-4182. doi:10.1523/JNEUROSCI.5471-07.2008.
19. Brand MD, Nicholls DG. Assessing mitochondrial dysfunction in cells. Biochem J. 2011;435:297-312. doi: 10.1042/BJ20110162.
20. Starkov AA. Measurement of mitochondrial ROS production. Methods Mol Biol. 2010;648:245-255. doi: 10.1007/978-1-60761-756-3-16.
21. Shih AY, Li P, Murphy TH. A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo. J Neurosci. 2005;25:10321-10335. doi: 10.1523/JNEUROSCI.4014-05.2005.
22. Bell KF, Al-Mubarak B, Fowler JH, Baxter PS, Gupta K, Tsujita T, et al. Mild oxidative stress activates Nrf2 in astrocytes, which contributes to neuroprotective ischemic preconditioning. Proc Natl Acad Sci USA. 2011;108:E1-2; author reply E3. doi: 10.1073/pnas.1015229108.
23. Haskew-Layton RE, Payappilly JB, Smirnova NA, Ma TC, Chan KK, Murphy TH, et al. Controlled enzymatic production of astrocytic hydrogen peroxide protects neurons from oxidative stress via an Nrf2-independent pathway. Proc Natl Acad Sci USA. 2010;107:17385-17390. doi: 10.1073/pnas.1003996107.
24. Escoté X, Miranda M, Menoyo S, Rodríguez-Porrata B, Carmona-Gutiérrez D, Jungwirth H, et al. Resveratrol induces antioxidant defence via transcription factor Yap1p. Yeast. 2012;29:251-263. doi: 10.1002/yea.2903.
25. Sun W, Wang W, Kim J, Keng P, Yang S, Zhang H, et al. Anti-cancer effect of resveratrol is associated with induction of apoptosis via a mitochondrial pathway alignment. Adv Exp Med Biol. 2008;614:179-186. doi: 10.1007/978-0-387-74911-2-21.
26. Puisieux F, Deplanque D, Bulckaen H, Maboudou P, Gelé P, Lhermitte M, et al. Brain ischemic preconditioning is abolished by antioxidant drugs but does not up-regulate superoxide dismutase and glutathion peroxidase. Brain Res. 2004;1027:30-37. doi: 10.1016/j.brainres.2004.08.067.
27. Holmström KM, Baird L, Zhang Y, Hargreaves I, Chalasani A, Land JM, et al. Nrf2 impacts cellular bioenergetics by controlling substrate availability for mitochondrial respiration. Biol Open. 2013;2:761-770. doi:10.1242/bio.20134853.
28. Greco T, Fiskum G. Brain mitochondria from rats treated with sulforaphane are resistant to redox-regulated permeability transition. J Bioenerg Biomembr. 2010;42:491-497. doi: 10.1007/s10863-010-9312-9.